Massachusetts General Hospital/Dana Farber Cancer Institute

Boston, Massachusetts 02114

1 studies enrolling now · 8 studies all time

What they study most

Advanced Relapsed Tumors, Advanced Solid Tumor, Advanced Solid Tumors, CRC, Cancer, Colorectal Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma HNSCC, Invasive Ductal Breast Carcinoma, Mesothelioma, Mesothelioma, Malignant

Studies at this site

• Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells — Recruiting now
• Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing — Recruiting now
• BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer — Status unconfirmed
• A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) — Stopped early
• Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung — Stopped early
• Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients — Completed
• A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 — Completed
• SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma — Completed